HeartSciences Secures FDA Breakthrough Designation for AI-ECG

Introduction

HeartSciences Inc. (NASDAQ: HSCS) is a medical technology company focused on applying artificial intelligence to standard electrocardiography (ECG) tests. Founded in 2008 and headquartered in Southlake, Texas, the company aims to enhance the clinical utility of the ECG by enabling the detection of structural and functional heart disease at the point of care.

Corporate Structure

As of mid-2025, HeartSciences employs between 11 and 50 people. The executive leadership team includes Chief Executive Officer Andrew Simpson, a Chief Operating Officer, a Chief Financial Officer, and a Vice President of Research and Development. The board of directors comprises clinicians and academic experts, including Dr. Jordan Strom from Harvard Medical School and Dr. Joshua M. Lampert from Mount Sinai Fuster Heart Hospital.

AI ECG by Nathan Trampe

Recent Developments and News

On June 5, 2025, the U.S. Food and Drug Administration granted Breakthrough Device designation to HeartSciences’ MyoVista Insights™ AI-ECG algorithm for detecting moderate-to-severe aortic stenosis. This algorithm was developed using convolutional neural networks trained on over 120,000 ECG records and is designed for integration with hospital electronic health record systems via the MyoVista Insights™ cloud platform, without requiring additional hardware.

On June 3, 2025, HeartSciences received a foundational U.S. patent covering the estimation of heart function measures from ECG signals. This patent enhances the company’s intellectual property portfolio in AI-enhanced electrocardiology.

HeartSciences filed a Form 8-K on July 1, 2025, to report material events under items 5.03 and 9.01. Additionally, two Form 8-K filings on June 4, 2025, disclosed governance updates and significant operational changes.

Financial and Strategic Analysis

On July 11, 2025, HeartSciences’ share price closed at $4.2770, down 25.36% from the prior session, with a trading volume of 207,129 shares. The 52-week trading range is $2.36 to $6.47, and the company’s market capitalization is approximately $4.6 million based on 1.08 million outstanding shares.

HeartSciences is pursuing a dual-track commercialization strategy. Its MyoVista® wavECG™ hardware platform is pending U.S. Food and Drug Administration clearance, while the MyoVista Insights™ cloud solution provides AI-enhanced results using existing ECG devices. Early adopter programs are in place in the U.K., and collaboration agreements exist with institutions including the Icahn School of Medicine at Mount Sinai and Rutgers University Hospital.

Medicare established a $128 reimbursement rate for AI-ECG procedures in January 2025, in addition to the $60 rate for conventional ECGs. HeartSciences aims to utilize this reimbursement framework following FDA clearance of its wavECG™ device, which is anticipated in 2025.

Market Position and Industry Context

Approximately one billion ECGs are performed globally each year; however, conventional ECGs primarily detect rhythm disorders. HeartSciences addresses a diagnostic gap by using AI to identify structural and functional abnormalities—such as aortic stenosis, left ventricular dysfunction, and valve disease—in asymptomatic or under-evaluated patients. The company's library of AI-ECG algorithms is among the largest in the industry, positioning it to serve primary care, emergency, and remote-monitoring settings. Cardiovascular disease accounted for approximately 19.9 million deaths worldwide in 2021, highlighting the need for effective detection tools.

TL;DR

• June 5, 2025: FDA grants Breakthrough Device designation for HeartSciences’ aortic stenosis AI-ECG algorithm.
• June 3, 2025: Company receives foundational U.S. patent for ECG-based heart function estimation.
• July 11, 2025: Shares close at $4.2770 (–25.36%) with a trading volume of 207,129; market cap ≈$4.6 million.
• FDA clearance for the MyoVista® wavECG™ device is expected in 2025; Medicare reimburses AI-ECG at $128 per test as of January 2025.